Industry report calls for greater investment in pain and addiction therapies

13 February 2018

A new report from USA-based Biotechnology Innovation Organization (BIO) advocates greater levels of investment in analgesics and addiction therapeutics.

The biotech trade group claims that “the addiction pipeline has 10-fold fewer clinical-stage programs than pain, suggesting a need for incentivizing innovation in this space.”

An analysis of the current pipeline of therapies and last decade of clinical trial activity reveals the current pain pipeline consists of 215 clinical-stage drug programs, with 125 testing novel chemical entities in the clinic, 87% of which are for non-opioid receptors.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK